You just read:

Aurigene Announces the Exercise of Curis' Option for CA-327 (PD-L1/TIM-3 Small Molecule Antagonist), The Third Program Under Its Collaboration, License and Option Agreement of January, 2015 (October 11, 2016, New Jersey, NJ, USA)

News provided by

Aurigene Discovery Technologies Limited

Oct 11, 2016, 08:46 ET